Cervical cancer as one of the most common malignant tumors in the female reproductive system , threatens tens of thousands women′s lives and health globally .The persistent infection of high-risk human papillomavirus ( HPV ) is directly related to the occurrence and development of cervical cancer ,as widely recognized by the academia .Therefore HPV prophylactic vaccines and therapeutic vaccines have been produced based on HPV infections .At present ,HPV prophylactic vaccines have been implemented in the majority of the industrialized countries in America and Europe ,and new progress has been made in the development of therapeutic vaccines ,including peptide vaccine ,protein vaccine,live vector vaccines and DNA vaccines.Prophylactic vaccines provide limited benefits to patients with HPV infection .However,therapeutic vaccines can specifically remove virus and virus infected cells by activating cellular immunity ,which is expected to become a new way to treat HPV infected cervical cancer .%宮頸癌作為女性生殖系統(tǒng)中最常見的惡性腫瘤之一,威脅著全球數(shù)以萬(wàn)計(jì)女性的生命和健康.目前學(xué)術(shù)界公認(rèn),高危型人乳頭瘤病毒(HPV)的持續(xù)感染與宮頸癌的發(fā)生、發(fā)展直接相關(guān),因此以HPV感染為出發(fā)點(diǎn)相繼出現(xiàn)了HPV預(yù)防性疫苗和治療性疫苗.目前,HPV預(yù)防性疫苗已經(jīng)開始逐漸應(yīng)用于美國(guó)及歐洲等多數(shù)發(fā)達(dá)國(guó)家,治療性疫苗的研制也取得了新的進(jìn)展,其中主要包括肽疫苗、蛋白疫苗、活載體疫苗及DNA疫苗等.然而,預(yù)防性疫苗對(duì)已感染HPV患者的治療效果有限,治療性疫苗則可以通過激活細(xì)胞免疫特異性地清除病毒和被病毒感染的細(xì)胞,有望成為治療HPV感染宮頸癌的新手段.
展開▼